Drug Topics July 4, 2024
“Adding this technology to our pandemic flu toolkit enhances our ability to be nimble and quick against the circulating strains and their potential variants,” said Dawn O’Connell, assistant secretary for preparedness and response at the HSS.
The US Department of Health and Human Services (HHS) will award $176 million to pharmaceutical and biotechnology company Moderna for the development of an mRNA-based pandemic influenza vaccine, according to a news release.1
Building on the technology proven effective in its COVID-19 vaccine, this award supports Moderna in establishing additional capabilities to rapidly develop and manufacture mRNA vaccines in response to future pandemics. The project will utilize existing facilities for large-scale mRNA production and ongoing seasonal flu vaccine research.
“We have successfully taken...
Today's Sponsors
Today's Sponsor